Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > We Asked For It

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Oct 27, 2021 3:35pm

103 Views

Post# 34055933

RE:RE:RE:We Asked For It

Have we heard these nebulous time estimates before

"pushed back our anticipated timeline for marketing application submission by several weeks..."

"The company looks forward to revealing the precommercial device to the market and submitting its marketing application submission to regulators in the weeks to come."

This is the old "lipstick on a pig". I was truly hoping for something positive in this update but unfortunately it was not to be.